Search research articles
Contact Us
Filters
Showing results (161-170 of 184) with videos related to
Page
of 19
Sort By:
Oral Oncology
|
April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial
Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, et al.
Lancet (London, England)
|
November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J Harrington, Richard Greil, et al.
Cancer Discovery
|
November 6, 2012
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation
Anna Sukhanova, Andrey Gorin, Ilya G Serebriiskii, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 21, 2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Canhua Xiao, Andrew H Miller, Gang Peng, et al.
Journal of the National Cancer Institute
|
September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
JCO Oncology Advances
|
April 2, 2026
Functional impact of transoral surgery and risk-based adjuvant therapy in human papillomavirus-associated oropharyngeal cancer: swallowing outcomes from ECOG-ACRIN E3311
Katherine A Hutcheson, Yael Flamand, Beatrice Manduchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Julie R Brahmer, Georgina V Long, Omid Hamid, et al.
Cancer
|
March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
JAMA Oncology
|
June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Barbara Burtness, Robert Haddad, José Dinis, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 184) with videos related to
Sort By:
Page
of 19
Oral Oncology
|
April 5, 2022
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048
Danny Rischin, Kevin J Harrington, Richard Greil, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 22, 2024
Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial
Marcin Dzienis, Juan Cundom, Christian Sebastian Fuentes, et al.
Lancet (London, England)
|
November 5, 2019
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Barbara Burtness, Kevin J Harrington, Richard Greil, et al.
Cancer Discovery
|
November 6, 2012
Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation
Anna Sukhanova, Andrey Gorin, Ilya G Serebriiskii, et al.
International Journal of Radiation Oncology, Biology, Physics
|
April 21, 2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Canhua Xiao, Andrew H Miller, Gang Peng, et al.
Journal of the National Cancer Institute
|
September 2, 2022
Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, et al.
JCO Oncology Advances
|
April 2, 2026
Functional impact of transoral surgery and risk-based adjuvant therapy in human papillomavirus-associated oropharyngeal cancer: swallowing outcomes from ECOG-ACRIN E3311
Katherine A Hutcheson, Yael Flamand, Beatrice Manduchi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 31, 2024
Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients
Julie R Brahmer, Georgina V Long, Omid Hamid, et al.
Cancer
|
March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
JAMA Oncology
|
June 14, 2019
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial
Barbara Burtness, Robert Haddad, José Dinis, et al.
Page
of 19